Clinical Trials
Efficacy Study of IMSA101 in Combination with Radiation and Immune Checkpoint Inhibitors in Patients with Oligoprogressive (OPD) and Oligometastatic (OMD) Solid Tumor Malignancies. IMSA101 is the first STING agonist to be advanced to randomized Phase 2 clinical studies.
ImmuneSensor is currently conducting randomized Phase 2 studies evaluating IMSA101 in combination with radiation and checkpoint inhibitors in patients with solid tumor malignancies. One study is an open-label, multicenter study evaluating the safety and efficacy of radiotherapy combined with immune checkpoint inhibitor (ICI) and IMSA101 in patients with oligoprogressive (OPD) solid tumor malignancies after prior PD-L1 or PD-1 targeted ICI immunotherapy. The second study is an open-label, multicenter study evaluating the safety and efficacy of radiotherapy combined with immune checkpoint inhibitor (ICI) and IMSA101 in patients with oligometastatic (OMD) NSCLC or renal cell carcinoma.
For more information on the ongoing trial, please visit clinicaltrials.gov